Ross Colin J D, Visscher Henk, Rassekh S Rod, Castro-Pastrana Lucila I, Shereck Evan, Carleton Bruce, Hayden Michael R
Department of Medical Genetics, University of British Columbia (UBC), Centre for Molecular Medicine and Therapeutics,
J Popul Ther Clin Pharmacol. 2011;18:e134-51. Epub 2011 Mar 21.
Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions.
药物不良反应（ADR）是发达国家中导致死亡和疾病的十大主要原因之一。在癌症治疗中，如今存活下来的癌症患者比以往任何时候都多，但40%的癌症幸存者会遭受危及生命或导致永久性残疾的严重药物不良反应，并伴有长期后遗症。药物不良反应在儿童中往往更频繁、更严重，而经历严重药物不良反应的儿童所面临的后果可能是灾难性的。药物基因组学有潜力提高这些药物的安全性。本综述重点介绍了癌症治疗中可能出现的、在儿童中更频繁且更严重的严重药物不良反应，以及旨在理解、预测并最终预防这些严重反应的药物基因组学研究。
